Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance

Potential U.S. clearance is targeted in approximately 15 months, subject to successful development and validation and FDA review.

Rhea-AI Summary

Autonomix Medical (AMIX) completed an FDA pre-submission meeting that informed its proposed U.S. regulatory pathway for a standalone sensing platform.

The company believes the feedback supports a Class II 510(k) pathway, using a previously cleared reference device to demonstrate substantial equivalence. Autonomix targets potential U.S. clearance in approximately 15 months, subject to successful development and validation activities and FDA review.

Development and validation will continue alongside work on signal interpretation and advanced computational capabilities. The company believes clearance could provide a regulatory reference for future platform generations, including planned signal interpretation and procedural guidance.

5 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointClass II 510(k) pathway is supported by FDA feedback, Autonomix believes, using a previously cleared reference device.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Potential U.S. clearance is targeted by Autonomix in approximately 15 months.
• Minor pointCompleted FDA pre-submission meeting provided guidance on regulatory strategy, validation activities and the anticipated submission pathway.
• Minor point. Forward-looking: it has not happened yet and may not happen.Future platform development includes planned signal interpretation and procedural guidance capabilities.
• Minor point. Forward-looking: it has not happened yet and may not happen.Standalone platform clearance could support future generations as a regulatory reference, Autonomix believes.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Clearance target depends on successful completion of development and validation activities and FDA review.

Argus 15 min delay 3 alerts

+0.27% vs previous close $3.76 last price 7.0x rel. volume Open Argus

Details

Market Reaction – AMIX

+2.0% Peak Tracked

$3.73 – $4.02 Day Range

$7.37M Market Cap

On Sep 30, the day this news came out, the latest delayed price for AMIX is 0.27% above the previous close. Argus tracked a peak move of +2.0% during the session. Our momentum scanner has recorded 3 alerts for this stock so far that day. The latest delayed price is $3.76. Relative volume is exceptionally heavy at 7.0x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Proposed device classification: Class II Targeted U.S. clearance timing: Approximately 15 months

Proposed device classification

Class II

Proposed pathway for the standalone sensing platform

Targeted U.S. clearance timing

Approximately 15 months

Company target, subject to development, validation, and FDA review

Key Terms

510(k), substantial equivalence

2 terms

510(k) regulatory

"Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance"

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

substantial equivalence regulatory

"use an already-cleared reference device to support a substantial-equivalence strategy"

A regulatory finding that a new medical device or product is comparable enough to an already-approved predicate item that it does not raise new questions about safety or effectiveness. For example under the U.S. FDA 510(k) process, a manufacturer shows the device has the same intended use and either the same technological characteristics or differences that do not introduce new risks; if accepted, the device can be cleared through the less burdensome pathway rather than a full premarket approval. The term denotes similarity for regulatory review, not a statement about identical performance in all situations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FDA pre-submission feedback supports a Class II strategy, leveraging substantial equivalence to a previously cleared device, positioning the Company for potential initial U.S. clearance of its standalone sensing platform in approximately 15 months

THE WOODLANDS, TX, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of a pre-submission meeting with the U.S. Food and Drug Administration (FDA) regarding the Company’s recently announced standalone transvascular sensing platform, which is designed to detect and differentiate faint biological signals.

The FDA interaction provided important guidance regarding Autonomix’s proposed regulatory strategy, validation activities and anticipated submission pathway for the Company’s standalone sensing platform. Based on feedback received, the Company believes it has identified a Class II regulatory pathway that would use an already-cleared reference device to support a substantial-equivalence strategy for its standalone sensing platform.

Subject to successful completion of development and validation activities, and FDA review, Autonomix is targeting potential U.S. clearance in approximately 15 months.

“This FDA interaction gives us greater clarity on the work required to pursue an initial U.S. clearance and represents a significant milestone in advancing our proprietary technology toward the U.S. market,” said Brad Hauser, Chief Executive Officer of Autonomix. “We believe a focused pathway for the standalone sensing platform allows us to pursue a nearer-term regulatory objective, while we continue to build toward the larger opportunity for our technology. Our goal is to establish the sensing foundation first, then expand toward biosignal interpretation and, over time, procedural guidance.”

Autonomix believes successful clearance of the standalone sensing platform could establish a regulatory predicate supporting future generations of its technology platform, including planned signal interpretation and procedular guidance capabilities.

“Our vision is a clear progression: sense, interpret and ultimately guide,” continued Mr. Hauser. “The ability to capture extremely faint biosignals at their source is the critical first step. From there, we believe we can build increasingly powerful computational capabilities, including artificial intelligence, designed to help physicians understand what is happening physiologically, where intervention may be appropriate and what changed following treatment. We believe this staged approach is a disciplined path from standalone sensing toward a broader 'Sense, Treat and Verify' platform. We look forward to sharing more in the coming months about how we plan to advance these capabilities.”

The Company will continue development and validation activities associated with its standalone sensing platform while advancing signal interpretation and other advanced computational capabilities for future generations of its platform.

About Autonomix Medical, Inc. 

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
 
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
 
Forward Looking Statements 

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include, but are not limited to, expectations regarding the Company’s anticipated regulatory pathway and strategy for its standalone sensing platform, including the potential for Class II clearance based on substantial equivalence, the anticipated timeline for potential U.S. clearance, the potential for a cleared standalone sensing platform to serve as a regulatory predicate for future product generations, the Company’s staged development plans for its platform, including potential signal interpretation and AI-enabled capabilities, the potential effectiveness and clinical benefits of Autonomix’s nerve-targeted treatments for pancreatic cancer pain and other conditions, the versatility and scalability of the Company’s platform technology, the potential for future clinical applications across multiple organ systems, and the strength and scope of the Company’s intellectual property portfolio.

Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor and Media Contact 

JTC Team, LLC 
Jenene Thomas
908.824.0775
autonomix@jtcir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What FDA pathway is Autonomix pursuing for its standalone sensing platform?

Autonomix believes FDA feedback supports a Class II 510(k) pathway using a previously cleared reference device to demonstrate substantial equivalence. The pre-submission meeting provided guidance on the proposed regulatory strategy, validation activities and anticipated submission pathway.

When does Autonomix target U.S. clearance for its standalone sensing platform?

Autonomix targets potential U.S. clearance in approximately 15 months, subject to successful completion of development and validation activities and FDA review.